Omeros (NASDAQ:OMER) Sets New 12-Month High on Better-Than-Expected Earnings

Omeros Corporation (NASDAQ:OMER) shares reached a new 52-week high during mid-day trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $18.14 and last traded at $17.2010, with a volume of 3092745 shares changing hands. The stock had previously closed at $13.71.

The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to analyst estimates of $12.69 million.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Significant earnings and revenue beats: Omeros reported second-quarter earnings of $0.02 per share, versus analysts’ expected loss of $0.27 per share and a $0.53 loss a year earlier. Revenue reached $28.53 million, more than double the $12.69 million consensus estimate. The results improved investor confidence in the company’s commercial performance. Omeros Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: YARTEMLEA momentum is supporting the outlook: Management highlighted strong early demand for YARTEMLEA, which is becoming an important commercial growth driver. Analysts also cited reduced competition in the C5 market as a positive factor for the product’s potential. Omeros Earnings Call: Yartemlia Surge and Leaner Balance Sheet
• Positive Sentiment: Balance-sheet and shareholder actions added to the catalyst: The earnings update emphasized debt reduction and a leaner balance sheet, while share repurchases provided an additional potential source of per-share support. OMER Stock Soars After YARTEMLEA Sales Momentum, Debt Reduction and Share Buybacks
• Positive Sentiment: Analyst remains bullish: H.C. Wainwright reiterated its Buy rating and maintained a $33 price target, citing YARTEMLEA’s launch trajectory and reduced C5 competition. This target is well above the stock’s recent trading range and reinforces the bullish reaction to the results. Omeros Maintained at Buy With $33 Price Target
• Neutral Sentiment: Reported short-interest data showed zero shares sold short, offering no meaningful short-squeeze or bearish-positioning signal.

Analyst Upgrades and Downgrades

OMER has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating on shares of Omeros in a report on Monday, July 27th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Tuesday, April 21st. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Wall Street Zen downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, June 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.00.

Insiders Place Their Bets

In other news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total transaction of $87,075.00. Following the sale, the director directly owned 35,067 shares in the company, valued at approximately $407,127.87. The trade was a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Omeros

A number of hedge funds have recently made changes to their positions in OMER. BlackRock Inc. bought a new stake in Omeros in the second quarter worth approximately $57,484,000. Vanguard Group Inc. increased its position in shares of Omeros by 19.9% during the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after acquiring an additional 666,357 shares in the last quarter. UBS Group AG raised its holdings in shares of Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after acquiring an additional 1,513,893 shares during the last quarter. Geode Capital Management LLC lifted its position in Omeros by 6.3% in the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock valued at $28,026,000 after acquiring an additional 95,979 shares in the last quarter. Finally, State Street Corp boosted its stake in Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock valued at $27,025,000 after purchasing an additional 333,798 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

Omeros Stock Up 24.6%

The stock has a market capitalization of $1.24 billion, a PE ratio of 24.53 and a beta of 2.54. The firm has a 50 day moving average price of $10.60 and a 200 day moving average price of $11.47.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.